TCIM
VKTX icon

TIAA CREF Investment Management’s Viking Therapeutics VKTX Stock Holding History

TIAA CREF Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.06M Buy
106,483
+8,004
+8% +$67K ﹤0.01% 2293
2018
Q4 		$753K Buy
98,479
+183
+0.2% +$2.19K ﹤0.01% 2396
2018
Q3 		$1.71M Buy
98,296
+1,562
+2% +$18.6K ﹤0.01% 2205
2018
Q2 		$918K Buy
+96,734
New +$643K ﹤0.01% 2529

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TIAA CREF Investment Management's VKTX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Viking Therapeutics (VKTX) stake by 8.1% in Q1 2019, buying an estimated $67K and bringing the position to 106,483 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

TIAA CREF Investment Management first reported a position in VKTX in Q2 2018 and has held it in 4 quarters since. The position peaked at $1.71M in Q3 2018. 164 funds tracked by Wall St. Rank hold VKTX as of Q1 2019.

  • TIAA CREF Investment Management held 106,483 shares of Viking Therapeutics worth $1.06M as of Q1 2019.
  • TIAA CREF Investment Management bought 8,004 Viking Therapeutics shares in Q1 2019, an estimated $67K.
  • Viking Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2293 holding.
  • TIAA CREF Investment Management first reported a position in Viking Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • TIAA CREF Investment Management's Viking Therapeutics position peaked at $1.71M in Q3 2018.
  • 164 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.